-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference.
Disumab has been recommended by the Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Prostate Cancer in 2021
.
——Professor Ye Dingwei from the Cancer Hospital of Fudan University Interview with Prostate cancer is one of the common malignant tumors in men, and its incidence ranks second in the world
.
With the increasing aging of the population, the incidence and death rate of prostate cancer are increasing year by year, seriously threatening men's health
.
In addition, prostate cancer is prone to bone metastasis, and it is relatively insidious when it occurs.
The patients are often at an advanced stage when they are diagnosed.
The median survival time of newly diagnosed prostate cancer patients who have developed bone metastasis is only 4-5 years
.
Compared with European and American countries, the incidence of metastatic prostate cancer in China is higher, but the survival rate is much lower
.
Recently, the "Expert Consensus on the Clinical Diagnosis and Treatment of Prostate Cancer Bone Metastasis and Bone-related Diseases (2021 Edition)" (hereinafter referred to as the "Consensus") was released.
What changes will this bring to the diagnosis and treatment of prostate cancer with bone metastases in my country? "Medical Oncology Channel" hereby invites the leading expert of "Consensus", Professor Ye Dingwei from Fudan University Cancer Hospital, to conduct an exclusive interview and organize it as follows for readers
.
Conforming to the needs of national conditions, focusing on the hot spots of prostate cancer bone metastasis In recent years, clinicians and prostate cancer patients have gradually increased their attention to tumor bone metastasis
.
Professor Ye Dingwei pointed out: "With the improvement of the people's living standards and the improvement of China's medical standards, the rate of patients seeking medical treatment has increased significantly, their survival period has also been significantly extended, and more and more attention has been paid to the details of major diseases
.
Take cancer as an example.
In the past, cancer treatment paid more attention to survival.
With the improvement of the treatment level and the general extension of the survival period of cancer patients, the attention of patients and their families gradually shifted to aspects closely related to the quality of life of patients, such as safety.
management, complications, treatment
.
In addition, with the popularization of the multidisciplinary comprehensive diagnosis and treatment (MDT) model of oncology, the close cooperation between different disciplines allows us to understand the characteristics of the disease more systematically and comprehensively
.
"Professor Ye Dingwei emphasized: "Bone is a common metastatic site of malignant tumors.
As clinicians pay more attention to bone metastasis, various tumor types have successively released the "bone metastasis consensus", which fully demonstrates the improvement in the standard of living and medical treatment in China.
Under the background of the general improvement of the level, clinical diagnosis and treatment are required to be more systematic, more detailed, and more personalized
.
Of course, the current clinical attention to bone metastasis of prostate cancer is not enough
.
The vast majority of prostate cancer patients with bone metastases do not have obvious symptoms or have atypical symptoms in the early stage.
Therefore, they are easily ignored by clinicians.
We urgently need to make more publicity and publicity on the research progress in related fields to improve clinicians’ understanding as soon as possible.
The importance of bone metastasis
.
"Understand bone metastasis and increase clinical attention.
To increase the attention to prostate cancer bone metastasis, we must first understand its characteristics
.
Ye Dingwei said: "Bone is the most common metastatic site of prostate cancer.
More than 70% of advanced prostate cancer patients will The occurrence of bone metastases and bone-related events (SREs), bone metastasis and its triggering of bone marrow compression, pathological fractures and other SREs seriously affect the quality of life of patients
.
The most common sites for prostate cancer bone metastasis are the pelvis and spine, and skull metastases are rare
.
The most common metastatic site in the peripheral bones is the limb bones, among which the femur is the most common
.
Bone metastases often cause bone-related events such as pain, pathological fractures, and spinal cord compression, and are accompanied by systemic symptoms such as fatigue, weight loss, and anemia.
If prostate cancer patients have these manifestations, the possibility of extensive bone metastasis should be considered
.
"So why does prostate cancer bone metastasis cause the above symptoms? 95% of prostate cancer bone metastases are osteogenic lesions, manifested by a pathological increase in the number of irregular bone trabeculae, and at the same time, the level of bone resorption markers will also increase.
Prove that osteogenic changes and osteolytic changes exist at the same time
.
From the molecular mechanism, prostate cancer cells can secrete related factors to promote the proliferation and differentiation of osteoblasts.
At the same time, circulating prostate cancer cells migrate into the bone marrow through blood.
Tumor cytokines stimulate osteoblasts to highly express RANKL (receptor activator of NF-κB ligand), promote the differentiation, activation and survival of osteoclasts, thereby degrading bone matrix and causing osteolysis change
.
prostate cancer bone metastasis status of the current therapeutic treatment of prostate cancer bone metastases mainly drug therapy, conventional analgesic treatment, external radiation therapy, radionuclide therapy, bone surgical treatment, minimally invasive treatment and other ways
.
Drug therapy is prostate The most important treatment for cancer bone metastasis is divided into systemic therapeutic drugs for tumor cells and bone protective agents for bone-related events.
The former includes endocrine therapy and chemotherapy, and the latter mainly includes bisphosphonates and RANKL inhibitors.
.
Bisphosphonate drugs such as zoledronic acid can significantly reduce bone-related events, especially pathological fractures, but no clinical studies have shown that they can bring survival benefits, and bisphosphonate drugs may cause renal function Serious adverse events such as injury and osteonecrosis of the mandible
.
"Disulumab is the first precisely targeted RANKL inhibitor.
It is a fully human monoclonal antibody used to prevent bone-related events in solid tumors.
It has a unique mechanism of action, namely targeting the RANK-RANKL-OPG axis.
, By blocking the combination of RANK-RANKL to inhibit the activity of osteoclasts, reduce bone resorption, promote bone remodeling, and reduce the occurrence of fractures
.
Clinical studies have shown that compared with zoledronic acid, disulumab can significantly delay healing To prevent the occurrence of bone-related events, the median time to the first bone-related event in prostate cancer patients treated with desulumab was 20.
7 months (significantly longer than zoledronic acid by 3.
6 months), which significantly reduced the initial or The risk of recurrence is up to 18%
.
Desulumab can also significantly delay the progression of pain by 8.
3 months (1.
4 months longer than zoledronic acid) [1]
.
In addition, the method of use of desulumab is subcutaneous injection.
Compared with the intravenous injection of zoledronic acid, the use of disulimab is more convenient, which can improve patient compliance, improve the patient’s bone health, and help patients improve their quality of life
.
Therefore, the drug was awarded the 2021 China Clinical The first-level recommendation of the Society of Oncology (CSCO) Guidelines for Diagnosis and Treatment of Prostate Cancer
.
"Professor Ye Dingwei introduced
.
The "Consensus" was released to help standardize the treatment of bone metastases from prostate cancer.
Clinicians provide more reasonable multidisciplinary diagnosis and treatment strategies for bone metastases of prostate cancer, reduce or delay the occurrence of bone-related events, improve the quality of life of patients, and reduce the impact of anti-tumor treatments and prolong the survival time of patients
.
"Consensus" is aimed at bone.
Metastasis mechanism, early identification and treatment of disease, etc.
, have been updated in conjunction with the latest diagnosis and treatment progress system
.
As prostate cancer treatment drugs become more and more abundant, there are also more choices of bone-modifying drugs from bisphosphonate drugs to more products such as desulumab.
Therefore, in the "Consensus", the use of desulumab is particularly Features and requirements have been clearly updated
.
It is believed that the popularization and promotion of the "Consensus" will provide strong support for improving the diagnosis and treatment of prostate cancer bone metastases in China
.
"Professor Ye Dingwei concluded
.
Consensus original: Professional Committee of Urinary and Male Reproductive System Tumors of Chinese Anti-Cancer Association.
Expert consensus on clinical diagnosis and treatment of bone metastasis and bone-related diseases of prostate cancer (2021 version) Expert profile Prof.
Ye Dingwei, Vice President of Fudan University Cancer Hospital, Chief Expert of Urinary Tumor MDT Shanghai Director of the City Institute of Urology and Oncology, Director of the Institute of Prostate Cancer, Fudan University, Director of the Chinese Association of Anticancer Association Urinary and Male Reproductive Tumor Committee (CACA-GU), Chairman of the Chinese Society of Clinical Oncology (CSCO) Prostate Cancer Expert Committee, Chinese Medical Association Vice Chairman of the Oncology Group of the Urology Branch (CUA) Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Urothelial Cancer Expert Committee Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Renal Cancer Expert Committee Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Vice-Chairman of the Committee of Immunotherapy Experts China Cancer Hospital Urinary Oncology Cooperative Group (UCOG) Chairman, Executive Director, China Anti-Cancer Association, Executive Director, Chinese Society of Clinical Oncology, China Anti-Cancer Association Urinary and Male Genital Tumor Committee (CACA-GU) Prostate Cancer Group Leader NCCN Kidney Cancer Diagnosis and Treatment Guidelines Chinese Edition Deputy Leader NCCN Prostate Cancer, Kidney Cancer, Bladder Cancer Asian Diagnosis and Treatment Consensus Expert Committee Member, Advanced Prostate Cancer Asia Pacific Consensus Expert Committee Member, Shanghai Medical Physician Association Urology Branch Vice Chairman The former chairman of the Shanghai Anti-Cancer Association, the second-review expert of the National Science Council, the president-elect of the Asia-Pacific Prostate Society (APPS), the vice president of the Asia-Pacific Society of Cryosurgery, and other references [1].
Smith MR, et al.
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer; comparison of skeletal-related events and symptomatic skeletal events[J].
Ann Oncol,2015,26(2):368-374.
[2].
Consensus original text: Chinese Anticancer Association Urology Male Reproductive System Tumor Professional Committee.
Expert consensus on the clinical diagnosis and treatment of bone metastases and bone-related diseases of prostate cancer (2021 edition)[J].
Chinese Journal of Oncology, 2021, 43(10):1016-1026.
*This article is only used to provide scientific information to medical professionals, and does not represent the views of this platform
Disumab has been recommended by the Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Prostate Cancer in 2021
.
——Professor Ye Dingwei from the Cancer Hospital of Fudan University Interview with Prostate cancer is one of the common malignant tumors in men, and its incidence ranks second in the world
.
With the increasing aging of the population, the incidence and death rate of prostate cancer are increasing year by year, seriously threatening men's health
.
In addition, prostate cancer is prone to bone metastasis, and it is relatively insidious when it occurs.
The patients are often at an advanced stage when they are diagnosed.
The median survival time of newly diagnosed prostate cancer patients who have developed bone metastasis is only 4-5 years
.
Compared with European and American countries, the incidence of metastatic prostate cancer in China is higher, but the survival rate is much lower
.
Recently, the "Expert Consensus on the Clinical Diagnosis and Treatment of Prostate Cancer Bone Metastasis and Bone-related Diseases (2021 Edition)" (hereinafter referred to as the "Consensus") was released.
What changes will this bring to the diagnosis and treatment of prostate cancer with bone metastases in my country? "Medical Oncology Channel" hereby invites the leading expert of "Consensus", Professor Ye Dingwei from Fudan University Cancer Hospital, to conduct an exclusive interview and organize it as follows for readers
.
Conforming to the needs of national conditions, focusing on the hot spots of prostate cancer bone metastasis In recent years, clinicians and prostate cancer patients have gradually increased their attention to tumor bone metastasis
.
Professor Ye Dingwei pointed out: "With the improvement of the people's living standards and the improvement of China's medical standards, the rate of patients seeking medical treatment has increased significantly, their survival period has also been significantly extended, and more and more attention has been paid to the details of major diseases
.
Take cancer as an example.
In the past, cancer treatment paid more attention to survival.
With the improvement of the treatment level and the general extension of the survival period of cancer patients, the attention of patients and their families gradually shifted to aspects closely related to the quality of life of patients, such as safety.
management, complications, treatment
.
In addition, with the popularization of the multidisciplinary comprehensive diagnosis and treatment (MDT) model of oncology, the close cooperation between different disciplines allows us to understand the characteristics of the disease more systematically and comprehensively
.
"Professor Ye Dingwei emphasized: "Bone is a common metastatic site of malignant tumors.
As clinicians pay more attention to bone metastasis, various tumor types have successively released the "bone metastasis consensus", which fully demonstrates the improvement in the standard of living and medical treatment in China.
Under the background of the general improvement of the level, clinical diagnosis and treatment are required to be more systematic, more detailed, and more personalized
.
Of course, the current clinical attention to bone metastasis of prostate cancer is not enough
.
The vast majority of prostate cancer patients with bone metastases do not have obvious symptoms or have atypical symptoms in the early stage.
Therefore, they are easily ignored by clinicians.
We urgently need to make more publicity and publicity on the research progress in related fields to improve clinicians’ understanding as soon as possible.
The importance of bone metastasis
.
"Understand bone metastasis and increase clinical attention.
To increase the attention to prostate cancer bone metastasis, we must first understand its characteristics
.
Ye Dingwei said: "Bone is the most common metastatic site of prostate cancer.
More than 70% of advanced prostate cancer patients will The occurrence of bone metastases and bone-related events (SREs), bone metastasis and its triggering of bone marrow compression, pathological fractures and other SREs seriously affect the quality of life of patients
.
The most common sites for prostate cancer bone metastasis are the pelvis and spine, and skull metastases are rare
.
The most common metastatic site in the peripheral bones is the limb bones, among which the femur is the most common
.
Bone metastases often cause bone-related events such as pain, pathological fractures, and spinal cord compression, and are accompanied by systemic symptoms such as fatigue, weight loss, and anemia.
If prostate cancer patients have these manifestations, the possibility of extensive bone metastasis should be considered
.
"So why does prostate cancer bone metastasis cause the above symptoms? 95% of prostate cancer bone metastases are osteogenic lesions, manifested by a pathological increase in the number of irregular bone trabeculae, and at the same time, the level of bone resorption markers will also increase.
Prove that osteogenic changes and osteolytic changes exist at the same time
.
From the molecular mechanism, prostate cancer cells can secrete related factors to promote the proliferation and differentiation of osteoblasts.
At the same time, circulating prostate cancer cells migrate into the bone marrow through blood.
Tumor cytokines stimulate osteoblasts to highly express RANKL (receptor activator of NF-κB ligand), promote the differentiation, activation and survival of osteoclasts, thereby degrading bone matrix and causing osteolysis change
.
prostate cancer bone metastasis status of the current therapeutic treatment of prostate cancer bone metastases mainly drug therapy, conventional analgesic treatment, external radiation therapy, radionuclide therapy, bone surgical treatment, minimally invasive treatment and other ways
.
Drug therapy is prostate The most important treatment for cancer bone metastasis is divided into systemic therapeutic drugs for tumor cells and bone protective agents for bone-related events.
The former includes endocrine therapy and chemotherapy, and the latter mainly includes bisphosphonates and RANKL inhibitors.
.
Bisphosphonate drugs such as zoledronic acid can significantly reduce bone-related events, especially pathological fractures, but no clinical studies have shown that they can bring survival benefits, and bisphosphonate drugs may cause renal function Serious adverse events such as injury and osteonecrosis of the mandible
.
"Disulumab is the first precisely targeted RANKL inhibitor.
It is a fully human monoclonal antibody used to prevent bone-related events in solid tumors.
It has a unique mechanism of action, namely targeting the RANK-RANKL-OPG axis.
, By blocking the combination of RANK-RANKL to inhibit the activity of osteoclasts, reduce bone resorption, promote bone remodeling, and reduce the occurrence of fractures
.
Clinical studies have shown that compared with zoledronic acid, disulumab can significantly delay healing To prevent the occurrence of bone-related events, the median time to the first bone-related event in prostate cancer patients treated with desulumab was 20.
7 months (significantly longer than zoledronic acid by 3.
6 months), which significantly reduced the initial or The risk of recurrence is up to 18%
.
Desulumab can also significantly delay the progression of pain by 8.
3 months (1.
4 months longer than zoledronic acid) [1]
.
In addition, the method of use of desulumab is subcutaneous injection.
Compared with the intravenous injection of zoledronic acid, the use of disulimab is more convenient, which can improve patient compliance, improve the patient’s bone health, and help patients improve their quality of life
.
Therefore, the drug was awarded the 2021 China Clinical The first-level recommendation of the Society of Oncology (CSCO) Guidelines for Diagnosis and Treatment of Prostate Cancer
.
"Professor Ye Dingwei introduced
.
The "Consensus" was released to help standardize the treatment of bone metastases from prostate cancer.
Clinicians provide more reasonable multidisciplinary diagnosis and treatment strategies for bone metastases of prostate cancer, reduce or delay the occurrence of bone-related events, improve the quality of life of patients, and reduce the impact of anti-tumor treatments and prolong the survival time of patients
.
"Consensus" is aimed at bone.
Metastasis mechanism, early identification and treatment of disease, etc.
, have been updated in conjunction with the latest diagnosis and treatment progress system
.
As prostate cancer treatment drugs become more and more abundant, there are also more choices of bone-modifying drugs from bisphosphonate drugs to more products such as desulumab.
Therefore, in the "Consensus", the use of desulumab is particularly Features and requirements have been clearly updated
.
It is believed that the popularization and promotion of the "Consensus" will provide strong support for improving the diagnosis and treatment of prostate cancer bone metastases in China
.
"Professor Ye Dingwei concluded
.
Consensus original: Professional Committee of Urinary and Male Reproductive System Tumors of Chinese Anti-Cancer Association.
Expert consensus on clinical diagnosis and treatment of bone metastasis and bone-related diseases of prostate cancer (2021 version) Expert profile Prof.
Ye Dingwei, Vice President of Fudan University Cancer Hospital, Chief Expert of Urinary Tumor MDT Shanghai Director of the City Institute of Urology and Oncology, Director of the Institute of Prostate Cancer, Fudan University, Director of the Chinese Association of Anticancer Association Urinary and Male Reproductive Tumor Committee (CACA-GU), Chairman of the Chinese Society of Clinical Oncology (CSCO) Prostate Cancer Expert Committee, Chinese Medical Association Vice Chairman of the Oncology Group of the Urology Branch (CUA) Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Urothelial Cancer Expert Committee Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Renal Cancer Expert Committee Vice Chairman of the Chinese Society of Clinical Oncology (CSCO) Vice-Chairman of the Committee of Immunotherapy Experts China Cancer Hospital Urinary Oncology Cooperative Group (UCOG) Chairman, Executive Director, China Anti-Cancer Association, Executive Director, Chinese Society of Clinical Oncology, China Anti-Cancer Association Urinary and Male Genital Tumor Committee (CACA-GU) Prostate Cancer Group Leader NCCN Kidney Cancer Diagnosis and Treatment Guidelines Chinese Edition Deputy Leader NCCN Prostate Cancer, Kidney Cancer, Bladder Cancer Asian Diagnosis and Treatment Consensus Expert Committee Member, Advanced Prostate Cancer Asia Pacific Consensus Expert Committee Member, Shanghai Medical Physician Association Urology Branch Vice Chairman The former chairman of the Shanghai Anti-Cancer Association, the second-review expert of the National Science Council, the president-elect of the Asia-Pacific Prostate Society (APPS), the vice president of the Asia-Pacific Society of Cryosurgery, and other references [1].
Smith MR, et al.
Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer; comparison of skeletal-related events and symptomatic skeletal events[J].
Ann Oncol,2015,26(2):368-374.
[2].
Consensus original text: Chinese Anticancer Association Urology Male Reproductive System Tumor Professional Committee.
Expert consensus on the clinical diagnosis and treatment of bone metastases and bone-related diseases of prostate cancer (2021 edition)[J].
Chinese Journal of Oncology, 2021, 43(10):1016-1026.
*This article is only used to provide scientific information to medical professionals, and does not represent the views of this platform
